Arteriocyte Magellan

Arteriocyte Medical Systems is a medical technology company that specializes in the development and commercialization of autologous cell therapy products. The company's flagship technology, the Magellan Autologous Platelet Separator System, is an automated bedside centrifuge designed to produce platelet-rich plasma (PRP) from a patient's own blood or bone marrow. This concentrated PRP is used in various clinical applications, including orthopedics, cardiovascular surgery, and chronic wound management, to facilitate tissue repair and healing. In October 2016, the company was acquired by Merit Medical Systems for approximately $35 million. The acquisition allowed Merit Medical to expand its presence in the regenerative medicine and interventional oncology markets. Today, the Magellan system continues to be a leading solution for point-of-care cell separation.